Epidermal growth factor reduces resistance to doxorubicin | Zendy

Kwok Tim T. | Zendy; Sutherland Robert M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Epidermal growth factor reduces resistance to doxorubicin

Author(s) -

Kwok Tim T.,

Sutherland Robert M.

Publication year - 1991

Publication title -

international journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.475

H-Index - 234

eISSN - 1097-0215

pISSN - 0020-7136

DOI - 10.1002/ijc.2910490114

Subject(s) - a431 cells , epidermal growth factor , epidermoid carcinoma , cell culture , biology , growth factor , epidermal growth factor receptor , doxorubicin , cell growth , growth inhibition , receptor , medicine , cancer research , cell , endocrinology , carcinoma , chemotherapy , biochemistry , cell cycle , oncogene , genetics

Epidermal growth factor (EGF) increased the sensitivity to doxorubicin (DOX) of a human squamous carcinoma cell line, A431. The relative enhancement of sensitivity by EGF was greater in 2 DOX‐resistant sublines, A431/A5 and A431/A10, established by growing cells from surviving colonies after treatment of A43I cells with DOX. A greater number of EGF receptors (both high‐ and low‐affinity binding sites) was found for resistant A431/A5 and A431/A10 cells than for parental cells. The enhanced drug responsiveness is not directly related to EGF effects on growth, as growth inhibition by EGF appears to be similar among the 3 sublines.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research